Denali Therapeutics Inc (DNLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has a cash flow conversion efficiency ratio of -0.116x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-107.30 Million) by net assets ($926.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Denali Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Denali Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Denali Therapeutics Inc for a breakdown of total debt and financial obligations.
Denali Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Denali Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zuger Kantonalbank
SW:ZUGER
|
0.074x |
|
Hangzhou Cable
SHG:603618
|
-0.069x |
|
Diodes Incorporated
NASDAQ:DIOD
|
0.020x |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
0.019x |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
N/A |
|
Privia Health Group Inc
NASDAQ:PRVA
|
0.161x |
|
CoCreation Grass Co Ltd
SHG:605099
|
0.002x |
|
P/f Bakkafrost
OL:BAKKA
|
0.098x |
Annual Cash Flow Conversion Efficiency for Denali Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see DNLI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.23 Billion | $-347.69 Million | -0.283x | +18.57% |
| 2023-12-31 | $1.03 Billion | $-357.99 Million | -0.347x | -47.92% |
| 2022-12-31 | $1.04 Billion | $-244.72 Million | -0.235x | -6.87% |
| 2021-12-31 | $962.29 Million | $-211.39 Million | -0.220x | -160.73% |
| 2020-12-31 | $1.15 Billion | $416.15 Million | 0.362x | +194.23% |
| 2019-12-31 | $394.89 Million | $-151.58 Million | -0.384x | -518.83% |
| 2018-12-31 | $546.85 Million | $50.12 Million | 0.092x | +155.70% |
| 2017-12-31 | $465.80 Million | $-76.64 Million | -0.165x | +42.13% |
| 2016-12-31 | $254.52 Million | $-72.36 Million | -0.284x | -129.53% |
| 2015-12-31 | $-15.63 Million | $-15.05 Million | 0.963x | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-… Read more